Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Novavax (NASDAQ:NVAX) shares fell on Tuesday after Citi started its coverage of the COVID shot maker with a Sell recommendation and a price target of $6, citing among other issues concerns over the ...

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

The vaccine is expected to be commercially ready for the 2025-2026 COVID-19 season. The Food and Drug Administration (FDA) has approved Nuvaxovid ™ (COVID-19 Vaccine, Adjuvanted) for active ...

The vaccine, called Nuvaxovid, is mainly intended for adults 65 or older. But people ages 12 to 64 with medical conditions that increase their risk of serious illness from COVID can also get the shot.

The company’s shot, called Nuvaxovid, could reshape the vaccine landscape as the pandemic grinds into its 32nd month. More protection for more people against ever-more-contagious new variants of ...

After years of strategic pivots and battling the bureaucracy, Novavax (NASDAQ:NVAX) has finally secured full FDA approval of their COVID-19 vaccine, NUVAXOVID. Not only does the BLA approval ...

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the FDA’s attitude toward mRNA and COVID-19 vaccines that have investors ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.